

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O: Box 1450 Alexandria, Virginia 22313-1450 www.aspib.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/943,664	08/30/2001	David Botstein	P2548P1C8 2448	
7590 07/07/2009			EXAMINER	
DDINIZE HOEED CH CON & LIONE				

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, IL 60610

ART UNIT

DATE MAILED: 07/07/2009

Please find below and/or attached an Office communication concerning this application or proceeding.

Notification of Non-Compliant Appeal Brief (37 CFR 41.37)

Ī	Application No.	Applicant(s)		
	09/943,664	BOTSTEIN ET AL.		
	Examiner	Art Unit		
	Christine J. Saoud	1647		

The Appeal Brief filed on 29 April 2009 is defective for failure to comply with one or more provisions of 37 CFR 41.37.

12	05.03	d dismissal of the appeal, applicant must file anamended brief or other appropriate correction (see MPEP 3) within ONE MONTH or THIRTY DAYS from the mailing date of this Notification, whichever is longer. SIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136.
1.	\boxtimes	The brief does not contain the items required under 37 CFR 41.37(c), or the items are not under the proper heading or in the proper order.
2.		The brief does not contain a statement of the status of all claims, (e.g., rejected, allowed, withdrawn, objected to, canceled), or does not identify the appealed claims (37 CFR 41.37(c)(1)(iii)).
3.		At least one amendment has been filed subsequent to the final rejection, and the brief does not contain a statement of the status of each such amendment (37 CFR 41.37(c)(1)(iv)).
4.		(a) The brief does not contain a concise explanation of the subject matter defined in each of the independent claims involved in the appeal, referring to the specification by page and line number and to the drawings, if any, by reference characters; and/or (b) the brief fails to: (1) identify, for each independent claim involved in the appeal and for each dependent claim argued separately, every means plus function and step plus function under 35 U.S.C. 112, sixth paragraph, and/or (2) set forth the structure, material, or acts described in the specification as corresponding to each claimed function with reference to the specification by page and line number, and to the drawings, if any, by reference characters (37 CFR 41.37(c)(1)(v)).
5.		The brief does not contain a concise statement of each ground of rejection presented for review (37 CFR 41.37(c)(1)(vi))
6.		The brief does not present an argument under a separate heading for each ground of rejection on appeal (37 CFR 41.37(c)(1)(vii)).
7.		The brief does not contain a correct copy of the appealed claims as an appendix thereto (37 CFR 41.37(c)(1)(viii)).
8.		The brief does not contain copies of the evidence submitted under 37 CFR 1.130, 1.131, or 1.132 or of any other evidence entered by the examiner and relied upon by appellant in the appeal , along with a statement setting forth where in the record that evidence was entered by the examiner, as an appendix thereto (37 CFR 41.37(c)(1)(ix)).
9.		The brief does not contain copies of the decisions rendered by a court or the Board in the proceeding identified in the Related Appeals and Interferences section of the brief as an appendix thereto (37 CFR 41.37(c)(1)(x)).
10	. 🛛	Other (including any explanation in support of the above items):
		See Continuation Sheet.
		/Christine J Saoud/ Primary Examiner, Art Unit 1647

⁻⁻The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

Continuation of 10. Other (including any explanation in support of the above items): Appellant indicates in the Brief that there are no Related Appeals and Interferences, except for the PRO247 application claiming the corresponding nucleic acids and issued as US Pat. 7,189,566 on 13 March 2007. In contrast, the Examiner is aware that there are appeals which may be related to, directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal (i.e. other polypeptide cases dependent solely on a postive gene amplification assay using nucleic acids). The Examiner does not know all these application unimbers. Appellant is required to submit "a statement identifying by application, patent, appeal or interference number all other prior and pending appeals, interferences or judicial proceedings know to appellant, the applealnst legal representative, or assignee which may be related increby affect or be directly affected by or have a bearing on the Board's decision in the pending appeal." Note MPEP 1205.02 makes clear that "the statement is not limited to copending applications." See also 30 CPR 41.37(c) and MPEP 1205.

Importantly, the Examiner is aware of at least one polypeptide case dependent solely on a postive gene amplification assay using nucleic acids in which the Board has rendered a decision (e.g. USSN 09904766, Appeal No. 2009-4086). MPEP 1205.02(ii) states: "Copies of any decisions rendered by a court or the Board in any proceeding identified under this paragraph must be included in an appendix as required by 3 CFR 41.37(CH)(N).